|2.||Hepatocellular Carcinoma (Hepatoma)
|1.||Trautwein, Christian: 52 articles (09/2015 - 06/2002)|
|2.||Liu, Ping: 48 articles (07/2015 - 08/2002)|
|3.||Brenner, David A: 46 articles (11/2015 - 01/2003)|
|4.||Sakaida, Isao: 46 articles (10/2015 - 01/2003)|
|5.||Tacke, Frank: 41 articles (09/2015 - 06/2002)|
|6.||Yoshiji, Hitoshi: 32 articles (03/2015 - 07/2002)|
|7.||Li, Jun: 31 articles (12/2015 - 05/2006)|
|8.||Fukui, Hiroshi: 31 articles (03/2015 - 07/2002)|
|9.||Weiskirchen, Ralf: 29 articles (12/2014 - 06/2002)|
|10.||Maehara, Yoshihiko: 28 articles (08/2015 - 01/2005)|
|1.||Carbon Tetrachloride (Tetrachloromethane)IBA
09/01/2014 - "To study the protective effects of HSYA on liver fibrosis induced by carbon tetrachloride (CCl4) and a high-fat diet (HFD), and to determine the mechanism of action of HSYA. "
09/01/2015 - "These observations are recapitulated in the well-established carbon tetrachloride model of liver fibrosis in which EphB2(-/-) carbon tetrachloride-treated mice showed a significant reduction of liver fibrosis compared to carbon tetrachloride-treated littermate mice. "
01/01/2015 - "In this study, we investigated their in vivo capabilities of homing and hepatocyte differentiation and therapeutic efficacy for liver disorders in carbon tetrachloride (CCl4)-induced liver fibrosis model mice. "
01/01/2014 - "This study aimed to investigate the therapeutic efficacy of bone marrow (BM)-derived MSCs and SIMV on carbon tetrachloride (CCl4)-induced liver fibrosis in rats. "
11/01/2015 - "Mesenchymal stem cells: In vivo therapeutic application ameliorates carbon tetrachloride induced liver fibrosis in rats."
11/01/2009 - "Concluding, HF improved the histology and serum biochemistry of liver cirrhosis, with an important reduction of interstitial collagen and increased extracelullar matrix degradation by reducing profibrotic gene expression."
06/01/2015 - "Mice receiving dietary CPS after BDL had a significant improvement of liver fibrosis accompanied by a decrease in collagen deposition and downregulation of activation markers in isolated HSCs. "
09/01/1999 - "Using in vivo fluorescence microscopy, characteristic microvascular features of CCl(4)-induced liver fibrosis, progressively observed within the 8-week period of toxin exposure, were the significant reduction in sinusoidal density; the increase of venular vascular space; the perivenular accumulation of Ito cells, with concomitant collagen deposition; and the collapse of parenchymal tissue. "
01/01/1991 - "Thus pharmacological inhibition of collagen deposition is likely to be beneficial for patients suffering from fibrotic disorders such as liver cirrhosis. "
04/01/1994 - "It was concluded that a heavy dosage of Paeonia rubra was effective in arresting the development of liver fibrosis, and in promoting the reabsorption of collagen fibres."
|3.||Biological Markers (Surrogate Marker)IBA
10/01/2009 - "Noninvasive serum markers offer considerable promise in their ability to stage liver fibrosis. "
08/01/2014 - "Review article: the efficacy of biomarkers in chronic fibroproliferative diseases - early diagnosis and prognosis, with liver fibrosis as an exemplar."
02/01/2012 - "Histopathological examination, estimation of biochemical markers, and grading of liver fibrosis was performed to evaluate pharmacodynamic efficacy of prepared formulation. "
01/01/2011 - "Liver biopsy represents the gold standard for damage evaluation, but noninvasive serum markers that mirror liver fibrosis progression are actual goals both in adults and especially in children. "
12/08/2006 - "In combination with clinical signs, ultrasound and biochemical markers noninvasive diagnosis of liver cirrhosis will be further improved."
01/01/2008 - "The aim of this study was to elucidate the efficacy of interferon (IFN) therapy in liver cirrhosis Japanese patients with genotype 1b and low virus load. "
12/01/2012 - "This work studied the impact of liver fibrosis on the efficacy of interferon in treating HCV."
01/01/2008 - "The efficacy of 24-week interferon monotherapy for type C liver cirrhosis in Japanese patients with genotype 1b and low virus load."
10/01/2014 - "In total 184 of 466 patients (39.5%) did not receive interferon-based therapy during the study period, with treatment withheld most frequently due to multiple clinical characteristics including hepatic cirrhosis (16.3%), thrombocytopaenia (16.3%) and age >60 years (10.9%). "
12/01/2013 - "This study confirms that the rate of liver fibrosis regression increases during the follow-up after SVR to interferon therapy in HIV-/HCV-coinfected patients."
06/20/2015 - "Compared with TA-S, TA-Gb-NPs significantly improved serum biochemical parameters in thioacetamide (TAA) induced liver fibrosis mouse model. "
05/25/2010 - "Histological analysis revealed that ginsenoside-Rg1 significantly improved the extent of liver fibrosis in rats induced by thioacetamide. "
01/01/2013 - "Rats with thioacetamide-induced liver cirrhosis were injected with the chimera to evaluate therapeutic efficacy. "
09/01/2008 - "This is the first study to demonstrate that knockdown of hepatic SPARC expression ameliorates thioacetamide-induced liver fibrosis in rats with chronic liver injury. "
05/01/2015 - "Rat liver fibrosis was induced with thioacetamide and the degree of liver fibrosis was determined using pathological diagnosis as a gold standard. "
|6.||Lamivudine (3TC)FDA Link
12/01/2003 - "Whether long-term lamivudine therapy is effective in HBV-related liver cirrhosis patients was prospectively evaluated. "
06/01/2006 - "The improvement in serum ALT and CP score at week 48 was similar irrespective of baseline decompensation, liver cirrhosis and the duration of overlap lamivudine therapy. "
09/15/2015 - "A proportion of HIV/HBV-coinfected patients on long-term lamivudine-containing ART had poor HIV and HBV suppression, drug resistance, and TE values indicative of advanced liver fibrosis. "
01/01/2007 - "Fifty-four patients (Child-Pugh A/B/C, 35/9/10) with HBV-related liver cirrhosis who had been treated with lamivudine for more than 12 months were evaluated. "
07/01/2006 - "The differences remained significant when only liver cirrhosis patients without HCC at presentation were analyzed, but the AUC of the two scores became comparable when patients on lamivudine were excluded. "
|7.||Ribavirin (Virazole)FDA LinkGeneric
01/01/2005 - "In conclusion, efficacy of combination therapy with IFNalpha and ribavirin in patients with liver cirrhosis is less effective and should be considered in chosen situations, especially in younger patients. "
01/01/2014 - "Clinical trials in HCV genotype 2/3 patients have demonstrated optimal efficacy in HCV-2, where the combination SOF/ribavirin (Rbv) for 12 weeks resulted in >90% sustained virological response (SVR) rates, while HCV-3 patients with advanced liver fibrosis and previous failure to PegIFN plus Rbv therapy still require individualized and optimized treatment strategies. "
08/28/2013 - "In the study's first part, 10 participants with early to moderate liver fibrosis were treated with 400 mg/d of sofosbuvir and weight-based ribavirin for 24 weeks. "
12/01/2015 - "Antiviral regimens including sofosbuvir are associated with success rates >90%, even in the case of "difficult-to-treat" patients such as subjects with liver cirrhosis as well as prior null response to IFN and ribavirin. "
01/01/2015 - "Inclusion criteria were HIV/HCV coinfection with advanced liver fibrosis and documented previous treatment failure on peginterferon-ribavirin. "
|8.||Non-alcoholic Fatty Liver DiseaseIBA
12/21/2011 - "IKK2 inhibitor IMD markedly improved non-alcoholic fatty liver disease in mice by lowering NF-κB activation, which could become a remedial target for liver fibrosis."
01/01/2011 - "Our results show that patients with biopsy-proven NAFLD have a significant reduction in serum sVEGFR-1 concentrations that predict the degree of liver fibrosis, independent of potential confounders."
01/01/2011 - "Liver stiffness measurement (LSM) is a noninvasive and reliable method for the indirect evaluation of liver fibrosis, but it may be less effective in case of nonalcoholic fatty liver disease (NAFLD). "
11/01/2015 - "In this study, we confirmed that serum Fuc-Hpt is suitable for the prediction of ballooning hepatocytes and that serum Mac2bp is suitable for the prediction of liver fibrosis severity in 124 biopsy-proven NAFLD patients (training cohort). "
03/01/2015 - "In our study we aimed to investigate whether the severity of liver fibrosis estimated with the NFS is associated with a higher risk of CHD among individuals with ultrasonography-diagnosed NAFLD. "
|9.||Hepatitis B Surface Antigens (HBsAg)FDA Link
07/15/2005 - "Our study showed that long-term hepatic complications occur in a significant proportion of HBsAg+ patients after HSCT and the incidence of liver cirrhosis is reduced in those with sustained serologic clearance of HBsAg after HSCT."
06/01/2009 - "Liver fibrosis improved in 70% of patients with HBsAg seroconversion compared to 30% of those without HBsAg seroconversion (p < 0.01). "
01/01/2009 - "Liver cirrhosis and HCC are relatively prevalent, and 80% to 85% of the patients with these conditions have positive results for hepatitis B surface antigen in Taiwan. "
07/01/2014 - "A total of 2,139 HBsAg-seropositive, anti-HCV-seronegative, and treatment-naïve participants without liver cirrhosis at study entry were included. "
10/01/2012 - "The aim of this study was to determine the dynamic expression profile of hepatitis B surface antigen (HBsAg) according to hepatic parenchyma cells' volume at different stages of liver fibrosis during the immune clearance phase. "
|10.||Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA
01/01/2009 - "We previously reported successful therapy of liver cirrhosis in rats using the hepatocyte growth factor gene. "
03/01/2010 - "Administration of exogenous hepatocyte growth factor (HGF) may be potentially useful for the treatment of liver fibrosis. "
03/01/2000 - "Hepatocyte growth factor gene therapy may have the potential to be useful for the treatment of patients with liver cirrhosis."
01/01/2015 - "Adenoviral delivery of truncated MMP-8 fused with the hepatocyte growth factor mutant 1K1 ameliorates liver cirrhosis and promotes hepatocyte proliferation."
08/01/2014 - "In this study, we demonstrate that hepatocyte growth factor (HGF), an antifibrotic factor in the process of pulmonary, renal and liver fibrosis, is a negative regulator of cardiac fibroblast transformation in response to transforming growth factor‑β1 (TGF‑β1). "
|1.||Transplantation (Transplant Recipients)
07/07/2001 - "For patients with cirrhosis, liver transplantation for HCC with one nodule less than 5 cm in diameter, or no more than three nodules each less than 3 cm, gives the best results with a 5-year survival rate of 70%. "
07/01/2012 - "Mice with BMSC transplantation with continuous CCl 4 injection had reduced liver fibrosis and a significantly improved expression of albumin compared with mice treated with CCl 4 alone. "
03/01/2015 - "Mesenchymal stem cell (MSC) transplantation was shown to be effective for the treatment of liver fibrosis, but the mechanisms of action are not yet fully understood. "
04/01/2013 - "Targeting AR, a key factor in male sexual phenotype, in BM-MSCs improves transplantation therapeutic efficacy for treating liver fibrosis."
12/01/2005 - "Should the patient progress to decompensated cirrhosis, liver transplantation is an effective treatment for AIH. "
05/18/2015 - "Liver transplantation (LT) provides the best chance of cure for patients with HCC and liver cirrhosis. "
06/01/2010 - "Liver transplantation has been the most effective treatment for patients with hepatic cirrhosis. "
08/01/2015 - "Between 2010-2011, 81 consecutive individuals with confirmed hepatic cirrhosis who were a candidate for liver transplantation were enrolled in this study. "
07/01/2015 - "A prospective single-center study investigated 174 patients undergoing liver transplantation due to acute decompensation of hepatitis B virus (HBV)-associated liver cirrhosis. "
04/01/2014 - "The aim of the study was to evaluate liver fibrosis by the ARFI with correlation of pathological stages in living donor liver transplantation (LDLT). "
03/01/2015 - "Therapeutic efficacy of splenectomy is attenuated by necroinflammation of the liver in patients with liver cirrhosis."
10/01/2014 - "We examined whether splenectomy improved liver fibrosis and caused immunological changes. "
04/01/1967 - "[The efficacy of splenectomy and portacaval tissue anastomoses in patients with liver cirrhosis]."
10/01/2015 - "Although studies have shown that splenectomy suppresses liver fibrosis, the mechanism by which this occurs is poorly understood. "
02/01/2014 - "The aim of the present study was to evaluate the long-term effects of splenectomy and subsequent IFN therapy in patients with hepatitis C virus (HCV)-related liver cirrhosis (LC). "
01/24/2015 - "After 6 more weeks of CCl4 injection (12 weeks in all), nude mice with hADMPCs transplants exhibited a significant reduction in liver fibrosis, as evidenced by Sirius Red staining, compared with nude mice treated with CCl4 for 12 weeks without hADMPCs transplants. "
09/01/2010 - "For the diagnosis of significant liver fibrosis in HCV transplant patients, the transient elastography reaches good results but cannot replace liver biopsy. "
09/01/2015 - "Doppler Ultrasound and Transient Elastography in Liver Transplant Patients for Noninvasive Evaluation of Liver Fibrosis in Comparison with Histology: A Prospective Observational Study."
05/14/2012 - "Recent studies have shown that post-liver transplant, there is a link between high levels of HCV replication, enhanced hepatocyte apoptosis and the subsequent development of rapidly progressive liver fibrosis. "
12/01/2006 - "We used DC-MRI to study 67 patients suffering from hepatic cirrhosis and on a waiting list for liver transplant. "
04/01/2005 - "BCAA supplementation after hepatectomy promotes rapid improvement in protein metabolism and inhibits progression to liver cirrhosis. "
02/01/1998 - "The HGF administration significantly improved liver fibrosis at the time of operation, attenuated the postoperative hepatic damage on histological examination, markedly accelerated the liver regeneration at 24 h after the hepatectomy. "
04/01/2006 - "We demonstrated the therapeutic efficacy of adenovirus-mediated HGF and TbetaTR gene transduction after partial hepatectomy for liver cirrhosis. "
01/01/1978 - "In the presence of a TAA-induced liver cirrhosis, liver regeneration 7 days after PCS and 70% hepatectomy is not improved by additional arterialization of the portal vein."
05/01/2011 - "The aim of this study was to assess the effect of preoperative and postoperative synbiotic treatment in hepatectomy patients with or without liver cirrhosis. "